血漿プロテアーゼC1阻害剤の世界市場レポート2025年

血漿プロテアーゼC1阻害剤の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR14.1%で65億3,000万米ドルに成長します。予測期間における主な促進要因としては、個別化治療アプローチの重視、臨床パイプラインにおけるC1阻害薬治療の開発進行、予防的治療法への嗜好の高まり、C1阻害薬の家庭用点滴ソリューションへのアクセスの拡大、術前および外科手術におけるC1阻害薬欠乏の認識の高まりなどが挙げられます。今後予想される注目すべき動向としては、希少疾病用医薬品の指定の増加、免疫原性の低い薬剤製剤の進歩、ゲノム技術の導入、遠隔医療プラットフォームへの拡大、長期にわたるC1阻害薬治療の革新などが挙げられます。

希少疾患への投資の増加は、血漿プロテアーゼC1阻害剤市場の成長を促進すると予想されます。希少疾患とは、人口のごく一部、典型的には2,000人に1人未満が罹患する健康状態のことです。これらの疾患は慢性的、進行性であることが多く、生命を脅かしたり、身体障害を引き起こすこともあります。投資の増加は、アンメット・メディカル・ニーズに対する認識の高まりと、希少疾病用医薬品の指定、市場独占権、開発コストの削減といった規制上のインセンティブにより、大きな利益を得られる可能性があることに起因しています。この投資は、遺伝性血管性浮腫や、重篤な症状を引き起こす可能性のあるC1インヒビター欠乏症に関連するその他の稀な疾患の治療を目的とした研究開発に資金を提供することで、血漿プロテアーゼC1阻害剤の開発を支援するものです。例えば、米国を拠点とする非営利団体世界・ジーンズは2024年4月、希少疾患の治療薬を開発する企業が2024年第1四半期に71億米ドルを調達したと報告し、2023年の同時期に調達した18億米ドルから307％増加しました。その結果、希少疾患への投資の増加が血漿プロテアーゼC1阻害剤市場を前進させています。

血漿プロテアーゼC1阻害剤市場の主要企業は、遺伝性血管性浮腫を迅速かつ効果的に緩和し、治療効果を高めるため、注射用処方薬などの先進製品の開発に注力しています。注射処方薬は注射によって投与され、血漿プロテアーゼC1阻害剤レベルを回復または置換することによって、炎症を制御し、腫脹エピソードを予防する働きをします。例えば、2022年12月、日本の製薬会社である武田薬品工業がインドでCINRYZEを発売しました。CINRYZEは、6歳以上の患者の予防的治療薬としてFDAに承認された初の注射用C1エステラーゼ阻害剤です。本剤は、C1-INHの血漿中濃度を上昇させることにより、遺伝性血管性浮腫（HAE）発作の頻度、重症度、持続時間を減少させ、ブラジキニンの過剰産生を防ぎ、それに伴う腫脹を抑制します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の血漿プロテアーゼC1阻害剤：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の血漿プロテアーゼC1阻害剤市場：成長率分析
• 世界の血漿プロテアーゼC1阻害剤市場の実績：規模と成長, 2019-2024
• 世界の血漿プロテアーゼC1阻害剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界の血漿プロテアーゼC1阻害剤：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の血漿プロテアーゼC1阻害剤市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• C1阻害薬
• C1エステラーゼ阻害剤
• 組み換え阻害剤
• カリクレイン阻害剤
• 選択的ブラジキニンB2受容体拮抗薬
• 世界の血漿プロテアーゼC1阻害剤市場剤形別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 凍結乾燥
• 注射剤
• 世界の血漿プロテアーゼC1阻害剤市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の血漿プロテアーゼC1阻害剤市場C1阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血漿由来C1インヒビター
• 組み換えC1阻害剤
• 世界の血漿プロテアーゼC1阻害剤市場C1エステラーゼ阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内（IV）C1エステラーゼ阻害剤
• 皮下（SC）C1エステラーゼ阻害剤
• 世界の血漿プロテアーゼC1阻害剤市場、組換え阻害剤のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 組み換えヒトC1インヒビター
• 組み換えアナログ阻害剤
• 世界の血漿プロテアーゼC1阻害剤市場カリクレイン阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血漿カリクレイン阻害剤
• 経口カリクレイン阻害剤
• 世界の血漿プロテアーゼC1阻害剤市場選択的ブラジキニンB2受容体拮抗薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射用B2受容体拮抗薬
• 経口B2受容体拮抗薬

第7章 地域別・国別分析

• 世界の血漿プロテアーゼC1阻害剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の血漿プロテアーゼC1阻害剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 血漿プロテアーゼC1阻害剤市場：競合情勢
• 血漿プロテアーゼC1阻害剤市場：企業プロファイル
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • CSL Behring LLC Overview, Products and Services, Strategy and Financial Analysis
  • Sigma-Aldrich Co. LLC Overview, Products and Services, Strategy and Financial Analysis
  • Octapharma AG Overview, Products and Services, Strategy and Financial Analysis
  • Bio-Techne Corp Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Ionis Pharmaceuticals Inc.
• Sanquin
• Biotest AG
• BioCryst Pharmaceuticals Inc.
• Pharming Group N.V.
• Sino Biological Inc
• Cayman Chemical
• Enzo Life Sciences Inc
• KalVista Pharmaceuticals Inc.
• Santa Cruz Biotechnology Inc
• Pharvaris N.V
• Attune Pharmaceuticals Inc.
• Biorbyt Ltd
• Adverum Biotechnologies Inc
• Lev Pharmaceuticals

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 血漿プロテアーゼC1阻害剤市場2029：新たな機会を提供する国
• 血漿プロテアーゼC1阻害剤市場2029：新たな機会を提供するセグメント
• 血漿プロテアーゼC1阻害剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Plasma protease C1-inhibitors are medications that suppress the activity of plasma protease C1 within the complement system. Their main function is to regulate immune system activity by preventing overactivation of the complement cascade and managing inflammation. These inhibitors help sustain equilibrium within immune and coagulation pathways, thereby protecting tissues from inflammatory damage.

The primary categories of medications that act on plasma protease C1-inhibitor include C1-inhibitors, C1-esterase inhibitors, recombinant inhibitors, kallikrein inhibitors, and selective bradykinin B2 receptor antagonists. C1-inhibitors are naturally occurring blood proteins that modulate the complement system, an essential part of the immune defense against infection and inflammation. These treatments are commonly available in injectable and lyophilized formulations and are distributed through hospital pharmacies, retail drugstores, and online pharmacy platforms.

The plasma protease C1-inhibitor market research report is one of a series of new publications from The Business Research Company that offers insights into plasma protease C1-inhibitor market statistics, including the global market size, regional distribution, leading competitors by market share, detailed market segmentation, industry trends, and emerging opportunities. This comprehensive research report provides an all-encompassing view of the industry, with detailed analysis of both the current landscape and future projections.

The plasma protease C1-inhibitor market size has grown rapidly in recent years. It will grow from $3.37 billion in 2024 to $3.85 billion in 2025 at a compound annual growth rate (CAGR) of 14.4%. Factors contributing to this historical growth include the rising prevalence of hereditary angioedema, increased awareness of rare genetic diseases, higher demand for biologics derived from plasma, improved diagnostics for C1-inhibitor deficiency, and expanded use of replacement therapy during emergency interventions.

The plasma protease C1-inhibitor market size is expected to see rapid growth in the next few years. It will grow to $6.53 billion in 2029 at a compound annual growth rate (CAGR) of 14.1%. Key drivers in the forecast period include a heightened emphasis on personalized treatment approaches, ongoing development of C1-inhibitor therapies in clinical pipelines, increasing preference for preventative treatment methods, broader access to at-home infusion solutions for C1-inhibitors, and greater recognition of C1-inhibitor deficiencies in preoperative and surgical contexts. Notable trends anticipated include a rise in orphan drug designations, advancements in low-immunogenicity drug formulations, incorporation of genomic technologies, expansion into telehealth platforms, and innovation in long-duration C1-inhibitor therapies.

The increasing investment in rare diseases is expected to drive the growth of the plasma protease C1-inhibitor market. Rare diseases are health conditions that impact a small percentage of the population, typically fewer than 1 in 2,000 individuals. These conditions are often chronic, progressive, and can be life-threatening or disabling. The rise in investment stems from the growing awareness of unmet medical needs and the potential for substantial returns through regulatory incentives such as orphan drug designation, market exclusivity, and lower development costs. This investment supports the development of plasma protease C1-inhibitors by funding research and innovation aimed at treating hereditary angioedema and other rare conditions linked to C1-inhibitor deficiencies, which can cause severe symptoms. For example, in April 2024, Global Genes, a US-based nonprofit organization, reported that companies developing drugs for rare diseases raised $7.1 billion in the first quarter of 2024, a 307% increase from the $1.8 billion raised in the same period in 2023. As a result, the increasing investment in rare diseases is propelling the plasma protease C1-inhibitor market forward.

Leading companies in the plasma protease C1-inhibitor market are concentrating on the development of advanced products, such as injectable prescription medicines, to provide rapid and effective relief for hereditary angioedema and enhance treatment results. Injectable prescription medicines are administered through injection and work by restoring or replacing plasma protease C1-inhibitor levels to control inflammation and prevent swelling episodes. For instance, in December 2022, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical firm, introduced CINRYZE in India. CINRYZE is the first injectable C1 esterase inhibitor approved by the FDA for prophylactic treatment in patients aged six years and older. It helps reduce the frequency, severity, and duration of hereditary angioedema (HAE) attacks by increasing plasma levels of C1-INH, thereby preventing excessive bradykinin production and controlling the associated swelling.

In December 2023, Danaher Corporation, a US-based conglomerate, acquired Abcam plc for $5.7 billion. This acquisition was intended to strengthen Danaher's life sciences portfolio by improving its protein research tools and accelerating progress in disease mapping and drug discovery. Abcam plc is a UK-based biotechnology firm that offers various products related to plasma protease C1-inhibitor.

Major players in the plasma protease c1-inhibitor market are Takeda Pharmaceutical Company Limited, CSL Behring LLC, Sigma-Aldrich Co. LLC, Octapharma AG, Bio-Techne Corp, Ionis Pharmaceuticals Inc., Sanquin, Biotest AG, BioCryst Pharmaceuticals Inc., Pharming Group N.V., Sino Biological Inc, Cayman Chemical, Enzo Life Sciences Inc, KalVista Pharmaceuticals Inc., Santa Cruz Biotechnology Inc, Pharvaris N.V, Attune Pharmaceuticals Inc., Biorbyt Ltd, Adverum Biotechnologies Inc, and Lev Pharmaceuticals.

North America was the largest region in the plasma protease C1-inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in plasma protease C1-inhibitor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the plasma protease C1-inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The plasma protease C1-inhibitor market consists of sales of berinert, cinryze, haegarda, firazyr, and lcatibant. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Plasma Protease C1-Inhibitor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on plasma protease c1-inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for plasma protease c1-inhibitor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The plasma protease c1-inhibitor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: C1-Inhibitors; C1-Esterase Inhibitor; Recombinant Inhibitor; Kallikrein Inhibitor; Selective Bradykinin B2 Receptor Antagonist
• 2) By Dosage Form: Lyphophlised; Injectables
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By C1-Inhibitors: Plasma-Derived C1-Inhibitor; Recombinant C1-Inhibitor
• 2) By C1-Esterase Inhibitor: Intravenous (IV) C1-Esterase Inhibitor; Subcutaneous (SC) C1-Esterase Inhibitor
• 3) By Recombinant Inhibitor: Recombinant Human C1-Inhibitor; Recombinant Analog Inhibitor
• 4) By Kallikrein Inhibitor: Plasma Kallikrein Inhibitor; Oral Kallikrein Inhibitor
• 5) By Selective Bradykinin B2 Receptor Antagonist: Injectable B2 Receptor Antagonist; Oral B2 Receptor Antagonist
• Companies Mentioned: Takeda Pharmaceutical Company Limited; CSL Behring LLC; Sigma-Aldrich Co. LLC; Octapharma AG; Bio-Techne Corp
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Plasma Protease C1-Inhibitor Market Characteristics

3. Plasma Protease C1-Inhibitor Market Trends And Strategies

4. Plasma Protease C1-Inhibitor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Plasma Protease C1-Inhibitor Growth Analysis And Strategic Analysis Framework

• 5.1. Global Plasma Protease C1-Inhibitor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Plasma Protease C1-Inhibitor Market Growth Rate Analysis
• 5.4. Global Plasma Protease C1-Inhibitor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Plasma Protease C1-Inhibitor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Plasma Protease C1-Inhibitor Total Addressable Market (TAM)

6. Plasma Protease C1-Inhibitor Market Segmentation

• 6.1. Global Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• C1-Inhibitors
• C1-Esterase Inhibitor
• Recombinant Inhibitor
• Kallikrein Inhibitor
• Selective Bradykinin B2 Receptor Antagonist
• 6.2. Global Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lyphophlised
• Injectables
• 6.3. Global Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of C1-Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Plasma-Derived C1-Inhibitor
• Recombinant C1-Inhibitor
• 6.5. Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of C1-Esterase Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous (IV) C1-Esterase Inhibitor
• Subcutaneous (SC) C1-Esterase Inhibitor
• 6.6. Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of Recombinant Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Human C1-Inhibitor
• Recombinant Analog Inhibitor
• 6.7. Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of Kallikrein Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Plasma Kallikrein Inhibitor
• Oral Kallikrein Inhibitor
• 6.8. Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of Selective Bradykinin B2 Receptor Antagonist, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable B2 Receptor Antagonist
• Oral B2 Receptor Antagonist

7. Plasma Protease C1-Inhibitor Market Regional And Country Analysis

• 7.1. Global Plasma Protease C1-Inhibitor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Plasma Protease C1-Inhibitor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Plasma Protease C1-Inhibitor Market

• 8.1. Asia-Pacific Plasma Protease C1-Inhibitor Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Plasma Protease C1-Inhibitor Market

• 9.1. China Plasma Protease C1-Inhibitor Market Overview
• 9.2. China Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Plasma Protease C1-Inhibitor Market

• 10.1. India Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Plasma Protease C1-Inhibitor Market

• 11.1. Japan Plasma Protease C1-Inhibitor Market Overview
• 11.2. Japan Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Plasma Protease C1-Inhibitor Market

• 12.1. Australia Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Plasma Protease C1-Inhibitor Market

• 13.1. Indonesia Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Plasma Protease C1-Inhibitor Market

• 14.1. South Korea Plasma Protease C1-Inhibitor Market Overview
• 14.2. South Korea Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Plasma Protease C1-Inhibitor Market

• 15.1. Western Europe Plasma Protease C1-Inhibitor Market Overview
• 15.2. Western Europe Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Plasma Protease C1-Inhibitor Market

• 16.1. UK Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Plasma Protease C1-Inhibitor Market

• 17.1. Germany Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Plasma Protease C1-Inhibitor Market

• 18.1. France Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Plasma Protease C1-Inhibitor Market

• 19.1. Italy Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Plasma Protease C1-Inhibitor Market

• 20.1. Spain Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Plasma Protease C1-Inhibitor Market

• 21.1. Eastern Europe Plasma Protease C1-Inhibitor Market Overview
• 21.2. Eastern Europe Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Plasma Protease C1-Inhibitor Market

• 22.1. Russia Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Plasma Protease C1-Inhibitor Market

• 23.1. North America Plasma Protease C1-Inhibitor Market Overview
• 23.2. North America Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Plasma Protease C1-Inhibitor Market

• 24.1. USA Plasma Protease C1-Inhibitor Market Overview
• 24.2. USA Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Plasma Protease C1-Inhibitor Market

• 25.1. Canada Plasma Protease C1-Inhibitor Market Overview
• 25.2. Canada Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Plasma Protease C1-Inhibitor Market

• 26.1. South America Plasma Protease C1-Inhibitor Market Overview
• 26.2. South America Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Plasma Protease C1-Inhibitor Market

• 27.1. Brazil Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Plasma Protease C1-Inhibitor Market

• 28.1. Middle East Plasma Protease C1-Inhibitor Market Overview
• 28.2. Middle East Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Plasma Protease C1-Inhibitor Market

• 29.1. Africa Plasma Protease C1-Inhibitor Market Overview
• 29.2. Africa Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Plasma Protease C1-Inhibitor Market Competitive Landscape And Company Profiles

• 30.1. Plasma Protease C1-Inhibitor Market Competitive Landscape
• 30.2. Plasma Protease C1-Inhibitor Market Company Profiles
  • 30.2.1. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. CSL Behring LLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sigma-Aldrich Co. LLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Octapharma AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bio-Techne Corp Overview, Products and Services, Strategy and Financial Analysis

31. Plasma Protease C1-Inhibitor Market Other Major And Innovative Companies

• 31.1. Ionis Pharmaceuticals Inc.
• 31.2. Sanquin
• 31.3. Biotest AG
• 31.4. BioCryst Pharmaceuticals Inc.
• 31.5. Pharming Group N.V.
• 31.6. Sino Biological Inc
• 31.7. Cayman Chemical
• 31.8. Enzo Life Sciences Inc
• 31.9. KalVista Pharmaceuticals Inc.
• 31.10. Santa Cruz Biotechnology Inc
• 31.11. Pharvaris N.V
• 31.12. Attune Pharmaceuticals Inc.
• 31.13. Biorbyt Ltd
• 31.14. Adverum Biotechnologies Inc
• 31.15. Lev Pharmaceuticals

32. Global Plasma Protease C1-Inhibitor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Plasma Protease C1-Inhibitor Market

34. Recent Developments In The Plasma Protease C1-Inhibitor Market

35. Plasma Protease C1-Inhibitor Market High Potential Countries, Segments and Strategies

• 35.1 Plasma Protease C1-Inhibitor Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Plasma Protease C1-Inhibitor Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Plasma Protease C1-Inhibitor Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer